Marinus Pharmaceuticals Inc (FRA:61Y)
€ 0.302 -0.002 (-0.66%) Market Cap: 17.09 Mil Enterprise Value: 30.25 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 37/100

Q1 2020 Marinus Pharmaceuticals Inc Earnings Call Transcript

May 04, 2020 / 12:30PM GMT
Release Date Price: €7 (-8.38%)
Operator

Greetings, and welcome to the Marinus Pharmaceuticals First Quarter 2020 Earnings Call. (Operator Instructions) As a reminder, this conference is being recorded.

It is now my pleasure to introduce your host, Sasha Damouni Ellis, Vice President, Investor Relations. Thank you. You may begin, Ms. Ellis.

Sasha Damouni Ellis;Scott Braunstein
Marinus Pharmaceuticals, Inc. - VP of IR & Corporate Communication;Marinus

Thank you. With me from Marinus are Dr. Scott Braunstein, Chief Executive Officer; Dr. Joe Hulihan, Chief Medical Officer; and Edward Smith, Chief Financial Officer.

Before we begin, I would like to remind everyone that some of the statements made today could be termed as forward-looking under the securities law. These forward-looking statements, of course, are subject to certain risk and uncertainties that are associated with our business and covered in part in the company's Form 10-K and 10-Q as filed with the Securities and Exchange Commission.

I will now turn the call over to Scott.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot